(Q34662825)

3 August 2017

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. (English)

1 reference

3 August 2017

phase III clinical trial

0 references

1 reference

Carmen J Allegra

1

1 reference

3 August 2017

Greg Yothers

2

1 reference

3 August 2017

Michael J O'Connell

3

1 reference

3 August 2017

Saima Sharif

4

1 reference

3 August 2017

Nicholas J Petrelli

5

1 reference

3 August 2017

Linda H Colangelo

6

1 reference

3 August 2017

James N Atkins

7

1 reference

3 August 2017

Thomas E Seay

8

1 reference

3 August 2017

Louis Fehrenbacher

9

1 reference

3 August 2017

Richard M Goldberg

10

1 reference

3 August 2017

Seamus O'Reilly

11

1 reference

3 August 2017

Luis Chu

12

1 reference

3 August 2017

Catherine A Azar

13

1 reference

3 August 2017

Samia Lopa

14

1 reference

3 August 2017

Norman Wolmark

15

1 reference

3 August 2017

language of work or name

English

0 references

publication date

12 October 2010

1 reference

Journal of Clinical Oncology

3 August 2017

1 reference

3 August 2017

29

1 reference

3 August 2017

11-16

1 reference

3 August 2017

1

1 reference

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer

3 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055856

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055856

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055856

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055856

FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055856

VEGF-targeted therapy: mechanisms of anti-tumour activity.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055856

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055856

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055856

Targeted agents for adjuvant therapy of colon cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055856

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055856

Statistical considerations in the intent-to-treat principle

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055856

Evaluation of survival data and two new rank order statistics arising in its consideration

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055856

Allocation of patients to treatment groups in a controlled clinical study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055856

Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055856

Cancer: The nuances of therapy.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055856

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055856

Hazard rate estimation under random censoring with varying kernels and bandwidths

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055856

Simultaneous inferences on the contrast of two hazard functions with censored observations

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055856

26 October 2018

Identifiers

DOI

10.1200/JCO.2010.30.0855

1 reference

3 August 2017

1 reference

3 August 2017

1 reference